T. Rowe Price Associates
AQST icon

T. Rowe Price Associates’s Aquestive Therapeutics AQST Stock Holding History

T. Rowe Price Associates’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$301K Buy
72,516
+16,565
+30% +$67.2K ﹤0.01% 2680
2025
Q4 		$362K Buy
55,951
+10,865
+24% +$67.7K ﹤0.01% 2551
2025
Q3 		$253K Buy
45,086
+2,144
+5% +$9.27K ﹤0.01% 2690
2025
Q2 		$143K Buy
42,942
+10,848
+34% +$31.1K ﹤0.01% 2815
2025
Q1 		$94K Buy
32,094
+4,425
+16% +$13.4K ﹤0.01% 2830
2024
Q4 		$99K Buy
27,669
+3,821
+16% +$17.6K ﹤0.01% 2831
2024
Q3 		$119K Hold
23,848
– – ﹤0.01% 2787
2024
Q2 		$0 Buy
+23,848
New +$79.7K ﹤0.01% 2926

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's AQST Position: Q1 2026 in Review

T. Rowe Price Associates increased its Aquestive Therapeutics (AQST) stake by 30% in Q1 2026, buying an estimated $67.2K and bringing the position to 72,516 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

T. Rowe Price Associates first reported a position in AQST in Q2 2024 and has held it in 8 quarters since. The position peaked at $362K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • T. Rowe Price Associates held 72,516 shares of Aquestive Therapeutics worth $301K as of Q1 2026.
  • T. Rowe Price Associates bought 16,565 Aquestive Therapeutics shares in Q1 2026, an estimated $67.2K.
  • Aquestive Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2680 holding.
  • T. Rowe Price Associates first reported a position in Aquestive Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • T. Rowe Price Associates's Aquestive Therapeutics position peaked at $362K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.